EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted urine metabolomics for enhanced diagnosis of hypoxic-ischemic encephalopathy in newborns: A pilot study

Darryl J Adamko iD, Maryam Alyari, Sibasis Daspal, Kim Davis, Jae Newton, Salah Almubarek, Anas El-Aneed

PLOS One · 10.11.2026 · 21 (11) · e0361619

DOI: 10.1371/journal.pone.0361619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 10.11.2026. Verfasst von Darryl J Adamko und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. Hauptthemen laut MEDLINE: Hypoxia-Ischemia, Brain, Metabolomics. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jim Pattison Childrens Hospital Foundation, CIHR, Saskatchewan Health Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While therapeutic hypothermia (cooling treatment) is successful in preventing hypoxic ischemic encephalopathy (HIE), current diagnosis is limited to clinical features and serum lactate. Many newborns at risk of HIE are not identified within the therapeutic window and consequently miss the opportunity for cooling treatment. We hypothesized that metabolomic analysis could more accurately identify infants at risk of HIE compared to other commonly used techniques, such as serum lactate. Newborns admitted for therapeutic hypothermia for HIE, were recruited (n = 11) and compared to four healthy infants. A targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) platform was used to measure metabolites in urine samples. We identified 15 metabolites that differentiated infants with HIE from healthy controls. The metabolomic signature was subsequently utilized to blindly and accurately re-identify the same infants 3 days later, after clinical recovery, with 100% accuracy, as their metabolic profiles resembled those of non-hypoxic healthy infants. The diagnostic performance of LC-MS/MS was superior to that of lactate alone. Urine metabolomic profiling has the potential to more accurately identify neonates at risk of long-term neurologic injury than lactate alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoxia-Ischemia, BrainMetabolomicsHumansInfant, NewbornPilot ProjectsFemaleMaleTandem Mass SpectrometryLactic AcidBiomarkersCase-Control StudiesChromatography, LiquidLiquid Chromatography-Mass SpectrometryHypothermia, Induced

Substanzen

Lactic AcidBiomarkers

Autor:innen und Institutionen

  • Department of Pediatrics, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • College of Nutrition & Pharmacology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

ORCID-Profile: Darryl J Adamko

Förderung

  • Jim Pattison Childrens Hospital Foundation
  • CIHR
  • Saskatchewan Health Research Foundation

Zitieren

APA

Adamko, D. J., Alyari, M., Daspal, S., Davis, K., Newton, J., Almubarek, S., & El-Aneed, A. (2026). Targeted urine metabolomics for enhanced diagnosis of hypoxic-ischemic encephalopathy in newborns: A pilot study. PLOS One, 21(11), e0361619. https://doi.org/10.1371/journal.pone.0361619

Vancouver

Adamko DJ, Alyari M, Daspal S, Davis K, Newton J, Almubarek S, et al. Targeted urine metabolomics for enhanced diagnosis of hypoxic-ischemic encephalopathy in newborns: A pilot study. PLOS One. 2026;21(11):e0361619. doi:10.1371/journal.pone.0361619

BibTeX
@article{Adamko2026,
  author = {Adamko, Darryl J and Alyari, Maryam and Daspal, Sibasis and Davis, Kim and Newton, Jae and Almubarek, Salah and El-Aneed, Anas},
  title = {Targeted urine metabolomics for enhanced diagnosis of hypoxic-ischemic encephalopathy in newborns: A pilot study},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {e0361619},
  doi = {10.1371/journal.pone.0361619}
}
Kostenlos starten →